Although Schlenck et al. showed that the combination of the mutations in FLT and NPM1 or CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA) could be used to predict NK-AML prognosis, most patients did not have this mutation set [3]. This evidence concerns the gene CEBPA and acute myeloid leukemia.